About: British Association for the Study of the Liver Annual Meeting 7-9 September 2011 Abstracts

Documentation

scienceplus.abes.fr version Bêta

scienceplus.abes.fr | explorer

À propos de : British Association for the Study of the Liver Annual Meeting 7-9 September 2011 Abstracts Goto Sponge NotDistinct Permalink

Attributs	Valeurs
type	work Issue
Is Part Of	http://hub.abes.fr/bmj/periodical/gut/2011/volume_60
Title	British Association for the Study of the Liver Annual Meeting 7-9 September 2011 Abstracts
has manifestation of work	http://hub.abes.fr/bmj/periodical/gut/2011/volume_60/issue_suppl2/m/print http://hub.abes.fr/bmj/periodical/gut/2011/volume_60/issue_suppl2/m/web
Date Copyrighted	2011
Rights	© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
issue	Suppl 2
is Is Part Of of	P36 Morbidity and mortality associated with varices in patients with primary biliary cirrhosis P57 The IL28B gene SNP rs12979860 CC haplotype, predictor of response to treatment in chronic HCV infection, is associated to high numbers of CD56bright NK cells, low numbers of CD3-CD56-CD16+ NK cells and low HCV-specific IL-10 production P75 Impaired cardiorespiratory reserve in primary biliary cirrhosis patients undergoing liver transplant assessment P79 Plasma succinylacetone is raised after liver transplantation for tyrosinaemia type 1 and is associated with reduced porphobilinogen synthase activity suggesting it is functional P61 Bone mineral density loss in tenofovir treated Chronic Hepatitis B Virus (HBV) patients is a consequence of Vitamin D deficiency and not Tenofovir therapy OP02 The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC OP08 NAFLD related HCC is rising dramatically in the North of England OP14 Identification and characterisation of a Novel Ly-6Cintermediate intrahepatic macrophage population which mediates the resolution of liver fibrosis, is induced by phagocytosis and can be manipulated therapeutically in vivo P34 No effect of tenofovir or entecavir on vitamin D levels in Chronic Hepatitis B mono-infected patients. Single centre ‘real life’ cohort experience P73 Preliminary results of the Study of Acute Liver Transplant (SALT): NSAID exposure and risk of acute liver failure leading to transplantation in 7 European countries P86 5α-reductase-1 knockout promotes steatosis but protects against hepatocarcinogenesis in a murine model of NAFLD P40 Fast track jaundice clinic: the standard of care for hepatobiliary malignancy? P62 Immunological analysis and clinical profile of Chronic Hepatitis B Virus (HBV) infection in the younger patient P63 Ribavirin uptake by primary human hepatocytes corresponds to equilibrative nucleoside transporter 1 expression OP06 Maternal obesity programs offspring innate immune dysregulation in non-alcoholic fatty liver disease P01 The effect of intraoperative N-acetylcysteine on hepatocellular injury during laparoscopic bariatric surgery: a randomised controlled trial P25 Fragility fracture risk in cirrhosis: a comparison of the fracture risk assessment tool (FRAX_), BSG and NICE guidelines P68 Is it worth testing unstable drug users for hepatitis C? P85 Human mesenchymal stem cells bind preferentially to injured liver in a β1-integrin and CD44 dependent manner P93 NFκB activation by TLR agonists is deficient in macrophages lacking STAT2 P17 TIPS outcomes for Budd-Chiari: a single tertiary centre experience P29 Reduced expression of Tim-3 renders Th1 and Th17 effector cells less amenable to T-reg control in autoimmune hepatitis P33 Serum total cortisol and plasma free cortisol response after low dose short synacthen test in stable cirrhosis P04 A dose effect of the disease risk gene HLA DR3 contributes to numerical and functional impairment of CD4+CD25+ regulatory T cells in patients with autoimmune hepatitis P44 Use of Intralipid infusion to analyse apolipoprotein B (apoB) and HCV RNA kinetics in chronic infection P60 Pre-treatment IP-10 concentrations are associated with a sustained virological response in HIV/HCV co-infected patients OP03 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results P16 Non-invasive evaluation of fibrosis in paediatric chronic liver disease P22 Gall bladder length on ultrsonography as a screening tool in identification of auto immune sclerosing cholangitis P56 What is the best method of case finding for chronic viral hepatitis in migrant communities? P31 Predictors of fluid responsiveness in patients with acute liver failure P32 Liver mobilisation during liver resection induces immediate and profound hepatocellular damage and inflammation in humans P58 Genetic, virological and immunological pre-treatment predictors of therapy response to Peg-IFN/ribavirin in children with chronic hepatitis C P88 Vascular adhesion protein-1 (VAP-1) modulates glucose and lipid uptake in Non-Alcoholic Fatty Liver Disease (NAFLD) P95 Molecular mechanisms of monocyte reprogramming in acute liver failure: importance of hepatically derived anti-inflammatory mediators P13 The performance validity of breath sample analysis in the diagnosis of hepatic encephalopathy in patients with cirrhosis P37 Platelet count and spleen size: avoidance of screening endoscopy for varices in patients with hepatitis C cirrhosis P65 Oral anti-viral therapy shaping the indications for hepatitis B liver transplantation over 2 decades P74 Hepatocyte transplantation in rats with acute liver failure using cells labelled with a clinical grade MRI contrast agent P76 Meta-analysis of published evidence supports use of King's College criteria over model for end stage liver disease in outcome prediction in acute liver failure P82 Haemoglobin level prior to liver transplantation: does it predict the outcome? P11 Induction of hyperammonaemia from the small and large intestine in patients with cirrhosis with magnetic resonance quantification of brain water and metabolites P24 Presence of impaired baroreceptor sensitivity is a poor prognostic marker in cirrhosis P64 Central nervous system involvement in patients with chronic hepatitis C virus infection and minimal liver disease P69 How to re-engage patients with Hepatitis C infection: linking to Methadone prescribing works P91 Dual mechanism of NK cell inhibition by the HCV core 35-44 peptide OP07 Phenotypic description of a large cohort of PSC patients in the UK P12 Measuring the effectiveness of a multidisciplinary NASH Clinic P47 De-novo antiviral therapy with nucleos(t)ide analogues in ‘real-life’ patients with chronic hepatitis B infection: comparison of virological responses between lamivudine + adefovir vs entecavir vs tenofovir therapy P102 CLEVER-1 mediates the transmigration of B cells across human hepatic sinusoidal endothelium P15 Multiple defects of the immunoregulatory system contribute to the development of autoimmune hepatitis P41 Liver disease-specific gene expression profile in hepatocellular carcinoma P45 Natural killer cell cytotoxicity is enhanced in injection drug users with apparent resistance to hepatitis C virus infection P77 A Pharmacist delivered stratified conversion protocol from Hepatitis B Immunoglobulin (HBIG) to tenofovir or entecavir is efficacious, safe and cost-effective for prevention of recurrence of Hepatitis B virus (HBV) in Liver Transplant (LT) recipients P94 Rapamycin helps maintain the regulatory phenotype of cytochrome P450IID6-specific Treg expanded from patients with autoimmune hepatitis type 2 by reducing the number of IFNγ+ cells P98 The effects of Th17 cytokines on liver parenchymal cells shape the microenvironment for local generation of Th17/Tc17 in inflammatory liver disease P10 Whole-exome-Sequencing-based discovery of novel syndromic form of neonatal cholestasis OP15 Discovery of new liver fibrosis markers in hepatitis C patients using proteomics P14 Phenotypic and functional profile of CD4posCD25high regulatory T cells in autoimmune hepatitis/systemic lupus erythematosus overlap syndrome P28 Defective T-regulatory function in autoimmune hepatitis may partially derive from a pro-inflammatory skewing of Gal9+T-regs P35 Long-term remission is achievable in autoimmune hepatitis using Tacrolimus or Mycophenolate mofetil and results in regression of fibrosis P70 Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV Treatment-Naïve patients: final results of phase 3 ADVANCE Study P92 CD161+ γ-δ T cells: defining their role in patients with and without chronic hepatitis C P96 Serum protein N-glycosylation as a biomarker of paediatric NAFLD P104 Coagulation proteins in liver fibrosis: a role for tissue factor and fibrin/fibrinogen P105 Biliary drainage in a rat: a long-term continuous drainage model resulting in liver damage and an altered FXR pathway, lipid and cholesterol metabolism OP10 End-stage methotrexate-associated chronic liver disease in the USA: interaction of drug, host and environmental factors P21 Actively injecting drug users can be successfully treated with antiviral therapy for HCV, are unlikely to be re-infected, and significantly reduce their illicit drug use P30 Lung injury and its prognostic significance in acute liver failure P38 Homodynamic effects of prolonged treatment with midodrine in non-azotemic pre-ascitic, ascitic and refractory ascites cirrhotic patients P42 Role of Acoustic Radiation Force Impulse (ARFI) elastography in the non-invasive assessment of liver fibrosis in chronic viral hepatitis: a simultaneous comparison with liver histology in a secondary care setting P59 Subanalyses of the Telaprevir lead-in arm in the realize study: response at week 4 is not a substitute for prior null response categorisation P72 Liver transplantation for familial amyloidosis; long-term data from the Familial Amyloid Polyneuropathy World Transplant Registry (FAPWTR) P78 Long-term antibiotic prescription in patients relisted for late hepatic artery thrombosis is associated with greater waiting list mortality independent of meld P84 Towards cell based therapy for α1-antitrypsin deficiency through targeted bi-allelic gene correction in human iPS cells P07 Socio-demographic and behavioural determinants of abnormal liver function in a multi ethnic population in the UK: the LOLIPOP study P99 FXR stimulation with INT-747 in a rat biliary drainage model protects from hepatocellular injury after loss of enterohepatic circulation P100 Liver transplantation (LT) results in reduced recipient Natural Killer (NK) cell activation with associated down regulation of activating receptors NKp30 and NKp46 but not NKG2D P27 Reduction in alanine aminotransferase values in diabetic patients receiving long-term oral antibiotics: does modulation of gut flora affect hepatic inflammation in non-alcoholic fatty liver disease? P67 Switch to other nucleos(t)ide analogues therapy in chronic hepatitis B cohort on long-term de-novo combination therapy with lamivudine plus adefovir: efficacy and safety P89 Osteopontin promotes lymphocyte recruitment in steatohepatitis OP05 The impact of comorbidities on outcome of patients assessed for liver transplantation, waiting list mortality and post liver transplantation survival using the Charlson comorbidity index OP11 Are simple non-invasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? OP12 Similar Svr Rates In Il28b Cc, Ct Or Tt prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the Realize Study OP13 CD8b low T cells are a prominent, functionally distinct population in chronic hepatitis B infection P19 Symptomatic Epstein Barr Virus (EBV) Hepatitis is uncommon, but occurs in patients of any age, including the elderly P23 Comparison of enhanced liver fibrosis test and transient elastography for the non-invasive assessment of liver fibrosis in chronic hepatitis B P49 Treating hepatitis C in the patient's home: a hospital and homecare partnership P66 Low pre-treatment plasma HBsAg level and its decline during add-on interferon treatment predict response to combined lamivudine/interferon therapy in tolerant children with infancy-acquired chronic hepatitis B P80 Patient characteristics and outcomes in a ‘Hub and Spoke Model’ for liver transplantation provision: The South West Liver Unit/King's College Experience P09 Validation of a novel biomarker model for the prediction of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata